🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion

Recruitingn/aAges 18 Years - anyAllNedim Tojaga
NCT06949319 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF. AF increases the risk of death, heart failure, and stroke, which severely affect patients and also lead to high healthcare costs. Around 25% of all strokes are caused by AF, and patients with stroke due to AF tend to have a higher risk of death and more disability compared to stroke patients without AF. Stroke prevention is, therefore, an important part of AF treatment, in which blood thinning medication has an important role. However, blood thinners increase the risk of bleeding. Therefore, it is important to divide patients with AF into different risk groups, known as risk assessment, to figure out who will benefit the most from blood thinners. To be able to divide patients into different risk groups, various stroke risk assessment tools have been

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with newly diagnosed non-valvular atrial fibrillation (NVAF), who are oral anticoagulant-naïve (OAC-naïve) prior to inclusion. * Age ≥ 18 years. * Signed informed consent. Exclusion Criteria: * Ongoing OAC treatment prior to inclusion. * Valvular AF (mechanical heart valves or moderate-severe mitral stenosis). * Secondary AF due to an acute reversible precipitant (e.g., infection, surgery, thyrotoxicosis, etc.). * Pregnant or breastfeeding women. * Treatment with oral contraceptives. * End-stage renal disease (creatinine clearance \<15 mL/min as calculated by the Cockcroft-Gault equation). * Connective tissue diseases. * Active cancer (cancer diagnosis not followed by curative procedures six months from the date of diagnosis). * Major surgery (\< three months). * Acute coronary syndrome, stroke/TIA, and venous thromboembolism within three months prior to inclusion. * Thrombophilia. * Significant liver disease. * Significant hematological disease.
💊

What it tests

  • Not listed
📍

Where

1 site
Esbjerg Hospital - University Hospital of Southern Denmark, involving collaboration between the Unit for Thrombosis Research, Department of Clinical Diagnostics and the Department of Cardiology.
Esbjerg, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy